Why Repros Therapeutics (RPRX) Stock Plummeted to a One-Year Low Today

NEW YORK (TheStreet) -- Shares of Repros Therapeutics  (RPRX) plummeted to a 52-week low of $8.88 on Thursday after an FDA panel put up a roadblock for the company's low-testosterone drug Androxal.

The panel expressed concern that doctors were prescribing Low T drugs too broadly to middle-aged men who wanted to increase their libidos, according to FierceBiotech. The panel voted Wednesday to advise the FDA to limit the use of such drugs to a specific medical purpose.

Most of the panel wanted pricey cardiovascular tests to determine the risks in using Low T drugs for age-related problems rather than for specific medical issues. Four panel members thought that these studies should occur no matter the circumstances.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Repros has been trying to show its yet-to-be-approved drug Androxal is a safer alternative to market leader AndroGel. The company has focused its studies on an obese patients with sexual issues.

RPRX Chart RPRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

8 Stocks Under $10 to Trade for Huge Profits

8 Stocks Under $10 to Trade for Huge Profits

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts